welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)
study id #: NCT03406780
condition: Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
status: active, not recruiting
purpose:HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne muscular dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month period.
intervention: CAP-1002, Placebo
mechanism of action: Cardiac progenitor cells to promote cellular regeneration
results: https://clinicaltrials.gov/ct2/show/results/NCT03406780
last updated: May 06, 2019
rareRelated
-
Edasalonexent could reduce functional decline in boys with DMD, MoveDMD phase 2 results suggestResults of the Phase 2 MoveDMD trial sho...
-
MoveDMD: phase 2 trial of edasalonexent, an NF-κB inhibitor, in 4 to 7-year old patients with Duchenne muscular dys...NF-κB is activated from infancy in DMD,...
-
Roche Letter to the Duchenne CommunityBy now, many have heard about Pfizer's d...
-
Phase IIb Study of PRO045 in Subjects With Duchenne Muscular DystrophyThe purpose of the study is to see wheth...
-
A Phase IIa Study of TAS-205 for Duchenne Muscular DystrophyThe objective of this study is to evalua...
-
Capricor places Duchenne drug trial on holdCapricor Therapeutics Inc said on Wednes...
-
PoC Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With DMDA Phase 2 Clinical Study to Assess the A...
-
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, ran...Background: Duchenne muscular dystrophy...